Skip to main content
Article thumbnail
Location of Repository

Decreased ADP-Ribosyl Cyclase Activity in Peripheral Blood Mononuclear Cells from Diabetic Patients with Nephropathy

By Michio Ohtsuji, Kunimasa Yagi, Miyuki Shintaku-Kubota, Yukiko Kojima-Koba, Naoko Ito, Masako Sugihara, Naoto Yamaaki, Daisuke Chujo, Atsushi Nohara, Yoshiyu Takeda, Junji Kobayashi, Masakazu Yamagishi and Haruhiro Higashida


Aims/hypothesis. ADP-ribosyl-cyclase activity (ADPRCA) of CD38 and other ectoenzymes mainly generate cyclic adenosine 5’diphosphate-(ADP-) ribose (cADPR) as a second messenger in various mammalian cells, including pancreatic beta cells and peripheral blood mononuclear cells (PBMCs). Since PBMCs contribute to the pathogenesis of diabetic nephropathy, ADPRCA of PBMCs could serve as a clinical prognostic marker for diabetic nephropathy. This study aimed to investigate the connection between ADPRCA in PBMCs and diabetic complications. Methods. PBMCs from 60 diabetic patients (10 for type 1 and 50 for type 2) and 15 nondiabetic controls were fluorometrically measured for ADPRCA based on the conversion of nicotinamide guanine dinucleotide (NGD+) into cyclic GDP-ribose. Results. ADPRCA negatively correlated with the level of HbA1c (P = .040, R2 = .073), although ADPRCA showed no significant correlation with gender, age, BMI, blood pressure, level of fasting plasma glucose and lipid levels, as well as type, duration, or medication of diabetes. Interestingly, patients with nephropathy, but not other complications, presented significantly lower ADPRCA than those without nephropathy (P = .0198) and diabetes (P = .0332). ANCOVA analysis adjusted for HbA1c showed no significant correlation between ADPRCA and nephropathy. However, logistic regression analyses revealed that determinants for nephropathy were systolic blood pressure and ADPRCA, not HbA1c. Conclusion/interpretation. Decreased ADPRCA significantly correlated with diabetic nephropathy. ADPRCA in PBMCs would be an important marker associated with diabetic nephropathy

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1998). A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1
  2. (1993). A single protein immunologically identified as CD38 displays NAD + glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes,”
  3. alloantigen. A cell surface glycoprotein that marks early B lineage cells and mature myeloid lineage cells in mice,”
  4. (2000). Angiotensin II stimulates cyclic ADP-ribose formation in neonatal rat cardiac myocytes,”
  5. (2002). Anti-CD38 autoantibodies: characterisation in new-onset type I diabetes and latent autoimmune diabetes of the adult (LADA) and comparisonwithotherisletautoantibodies,”Diabetologia,vol.
  6. at the junction between prognostic marker and therapeutic target,”
  7. (1999). Autoantibodies to CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in Caucasian patients with diabetes: effects on insulin release from human islets,” Diabetes,
  8. (2001). Autoantibody response toCD38inCaucasianpatientswithtype1andtype2diabetes: immunological and genetic characterization,”
  9. autoimmunity: recent advances and relevance to human diabetes,”
  10. (2007). b r a h a m i a n ,G .E n d l e r ,M .E x n e r ,e ta l . ,“ A s s o c i a t i o no f low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different genepolymorphisms of proinflammatory cytokines,”
  11. (2001). Biochemistry and molecular cell biology of diabetic complications,”
  12. (2000). CD38 expressed on human monocytes: a coaccessory molecule in the superantigen-induced proliferation,”
  13. (2001). CD38 expression and functional activities are up-regulated by IFN-γ on human monocytes and monocytic cell lines,”
  14. (1990). CD38 molecule: structural and biochemical analysis on human T lymphocytes,
  15. (1996). CD38-mediated growth suppression of B-cell progenitors requires activation of phosphatidylinositol 3-kinase and involves its association with the protein product of the c-cbl protooncogene,”
  16. (2003). CD38/cyclic ADP-ribose-mediated Ca 2+ signaling contributes to airway smooth muscle hyper-responsiveness,”
  17. (1994). CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR + CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels,”
  18. (1995). Cellular events in the evolution of experimental diabetic nephropathy,”
  19. (2002). Cyclic ADP-ribose (cADPR) and nicotinic acid adeninedinucleotidephosphate(NAADP):novelregulatorsof Ca
  20. (2001). Cyclic ADP-Ribose and NAADP: Structure, Metabolism and Functions,
  21. (2001). Cyclic ADP-ribose as a potential second messenger for neuronal Ca 2+ signaling,”
  22. (1993). Cyclic ADP-ribose in insulin secretion from pancreatic β cells,”
  23. (1998). Cyclic GMP-dependent and -independent effects on the synthesis of the calcium messengers cyclic ADP-ribose and nicotinic acidadeninedinucleotidephosphate,”TheJournalofBiological Chemistry,
  24. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications— part 1: diagnosis and classification of diabetes mellitus.
  25. (2005). Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy,”
  26. (2006). Discovery of a small-molecule inhibitor for kidney ADP-ribosyl cyclase: implication for intracellular calcium signal mediated by cyclic ADP-ribose,”
  27. (2008). Evolution and function of the ADP ribosylcyclase/CD38 gene family in physiology and pathology,”
  28. (2001). fi s t e r ,A .O g i l v i e ,C .P .d aS i l v a ,A .G r a h n e r t
  29. (1993). Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen
  30. (2008). Generation of nicotinic acidadeninedinucleotidephosphateandcyclicADP-riboseby glucagon-like peptide-1 evokes Ca 2+ signal that is essential for insulin secretion in mouse pancreatic islets,”
  31. (2001). Generation, control, and processing of cellular calcium signals,”
  32. (2003). Graeff,a n dH
  33. (1994). Graeff,T .F .W a l s e t h ,K .F r y x e l l ,W .D .B r a n t o n ,a n d
  34. (2001). Human antiCD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets,”
  35. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance,”DiabetesCare,vol.23,no.12,pp.1816–1822,2000.
  36. (1997). Increased expression of intercellular adhesion
  37. (1999). Inhibition of high glucose-induced protein mono-ADP-ribosylation restores neuritogenesis and sodium-pump activity in SY5Y neuroblastoma cells,”
  38. (2003). Intercellular adhesion molecule-1-deficient mice are resistant against renal injuryafterinductionofdiabetes,”Diabetes,vol.52,no.10,pp. 2586–2593,
  39. (1968). Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents,”
  40. (1976). Isolation of lymphocytes, granulocytes and macrophages,”
  41. (1968). Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation
  42. (1997). J.R.Gavin,K.G.M.M.Alberti,M.B.Davidson,etal.,“Report of the expert committee on the diagnosis and classification of diabetesmellitus,”DiabetesCare,vol.20,no.7,pp.1183–1197,
  43. (2003). metabolites:rolesof poly(ADP-ribose) and cyclic ADP-ribose in insulin secretion and diabetogenesis,”
  44. (2008). Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells,”
  45. (2008). Navarro-Gonz´ alez and C. Mora-Fern´ andez, “The role of inflammatory cytokines in diabetic nephropathy,”
  46. (2000). Physiological and pathological significance of the CD38-cyclic ADP-ribose signaling system,”
  47. (2001). Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers,”
  48. (2002). Recent advances in the Okamoto model: the CD38-cyclic ADP-ribose signal system and the regenerating gene protein (Reg)-Reg receptor system
  49. (2000). Regional variations in the incidence of end-stage renal failure in Japan,” T h eJ o u r n a lo ft h eA m e r i c a nM e d i c a l Association,
  50. (2006). Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of
  51. (2005). Role of cyclic ADP-ribose in Ca 2+-induced Ca 2+ release and vasoconstriction in small renal arteries,”
  52. (1997). Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy,”
  53. (1996). Secretion of IFN-γ, IL-6, granulocytemacrophage colony-stimulating factor and IL-10 cytokines after activation of human purified
  54. (2001). Significance of ectocyclase activity of CD38 in insulin secretion of mouse pancreatic islet cells,”
  55. (1999). Sympathetic potentiation of cyclic ADP-ribose formation in rat cardiac myocytes,”
  56. (1993). Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP,”
  57. (1997). The CD38-cyclic ADP-ribose signalling system in insulin secretion: molecular basis and clinical implications,”
  58. (2000). The versatility and universality of calcium signalling,”
  59. (2002). Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials,”
  60. (2003). Vasodilation by the calcium-mobilizing messenger cyclic ADP-ribose,”

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.